UBS maintained a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) but reduced its price target to $137 from $154, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback